Immune Checkpoint Inhibitor Islet Function Impairment Outcomes: A Meta-Analysis

A 2024 systematic review and meta-analysis of 31 randomized controlled trials with 15,417 cancer patients, assessing the risk of islet function impairment from immune checkpoint inhibitors. The dataset, authored by Qi Hu and published on figshare, includes pooled risk ratios for hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. The analysis compares outcomes between patients treated with ICPis and non-ICPis regimens.

Use Cases

• Assessing the relative risk of hyperglycemia based on pooled risk ratios from 31 RCTs.
• Comparing the incidence of severe (grade 3-5) islet function impairment between treatment groups.
• Identifying high-risk subgroups, such as patients with NSCLC or those on PD-1 inhibitors.
• Evaluating the differential risk between ICPis monotherapy and combination therapy with chemotherapy.

Strengths

• Analysis is based on 31 randomized controlled trials, a robust study design.
• Includes data from 15,417 patients, providing a substantial sample size.
• Results include specific risk ratios and 95% confidence intervals for multiple outcomes and subgroups.
• Protocol was registered with PROSPERO (CRD42025639629), indicating a structured methodology.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 397.9 KB file size suggests the dataset is a summary table, not the underlying patient-level data.

Provenance

Source

Systematic review and meta-analysis published on figshare by author Qi Hu.

Collection Method

Data was gathered by searching PubMed, Embase, Cochrane, CNKI, Wanfang, CBM, and VIP databases from inception to October 24, 2024.

Time Range

Studies from database inception to October 24, 2024.

Freshness

Last updated 2026-03-19 06:50:00; freshness should be verified.